.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Chinese Patent Office
Fuji
Julphar
Citi
Mallinckrodt
Boehringer Ingelheim
Chubb
Covington

Generated: November 22, 2017

DrugPatentWatch Database Preview

SOMATULINE DEPOT Drug Profile

« Back to Dashboard

What is the patent landscape for Somatuline Depot, and when can generic versions of Somatuline Depot launch?

Somatuline Depot is a drug marketed by Ipsen Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has seventy-one patent family members in seventeen countries and two supplementary protection certificates in two countries.

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lanreotide acetate profile page.

Summary for SOMATULINE DEPOT

Pharmacology for SOMATULINE DEPOT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SOMATULINE DEPOT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,582,591 Delivery of solid drug compositions► Subscribe
5,837,276 Apparatus for the delivery of elongate solid drug compositions► Subscribe
6,142,972 Method and apparatus for the delivery of elongate solid drug compositions► Subscribe
6,306,420 Methods and apparatus for the delivery of solid drug compositions► Subscribe
5,660,846 Methods and apparatus for the delivery of solid drug compositions► Subscribe
5,616,123 Delivery of solid drug compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SOMATULINE DEPOT

Country Document Number Estimated Expiration
Australia3398595► Subscribe
Japan4489186► Subscribe
Denmark1157703► Subscribe
World Intellectual Property Organization (WIPO)9607398► Subscribe
Denmark0779805► Subscribe
Australia3398295► Subscribe
Spain2169762► Subscribe
Denmark1270032► Subscribe
JapanH10508294► Subscribe
Austria346628► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SOMATULINE DEPOT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
037Luxembourg► Subscribe91037, EXPIRES: 20160511
2002 00032Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Deloitte
Chubb
Colorcon
Mallinckrodt
Accenture
Covington
Johnson and Johnson
Citi
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot